PSA水平是否影响前列腺穿刺方法的选择:MRI-超声融合靶向穿刺、经直肠超声系统穿刺或两者联合的比较
该回顾性研究纳入190例患者共215个病灶,均行MRI-超声融合靶向穿刺(MRI-TBx)和经直肠超声系统穿刺(TRUS-SBx),按PSA水平分层比较前列腺癌、临床显著前列腺癌和非临床显著前列腺癌的检出率。结论认为PSA 10.0-20.0 ng/ml患者中MRI-TBx联合TRUS-SBx可作为临床显著前列腺癌的标准检测方法;PSA>20.0和<10.0 ng/ml时两种方法均可能有效。
要点
- PSA 10.0-20.0 ng/ml组中,TRUS-SBx与联合方法对临床显著前列腺癌检出率差异有统计学意义(p=0.044)。
- PSA<10.0 ng/ml组中,MRI-TBx对前列腺癌和临床显著前列腺癌检出率高于TRUS-SBx,但差异无统计学意义(p=0.741;p=0.400)。
- PSA>20.0 ng/ml组中,MRI-TBx对临床显著前列腺癌检出率高于TRUS-SBx,但差异无统计学意义(p=0.600)。
核心结论
- PSA 10.0-20.0 ng/ml患者中,MRI-TBx联合TRUS-SBx可能适合作为临床显著前列腺癌的标准检测方法;PSA>20.0和<10.0 ng/ml时,MRI-TBx和TRUS-SBx均可能提供有效的肿瘤检测方案。
研究设计与样本
- 回顾性研究,纳入190例患者共215个病灶,均行MRI-TBx和TRUS-SBx,术前测量PSA并分为<10.0、10.0-20.0和>20.0 ng/ml三层。
诊断标准与关键数值
- 190例患者中组织病理学结果显示前列腺癌126例,其中临床显著前列腺癌119例;PSA<10.0 ng/ml组MRI-TBx与TRUS-SBx检出前列腺癌和临床显著前列腺癌差异无统计学意义(p=0.741;p=0.400);PSA 10.0-20.0 ng/ml组TRUS-SBx与联合方法检出临床显著前列腺癌差异有统计学意义(p=0.044);PSA>20.0 ng/ml组MRI-TBx与TRUS-SBx检出临床显著前列腺癌差异无统计学意义(p=0.600)。
临床应用与阅片要点
- 作者认为PSA 10.0-20.0 ng/ml患者中MRI-TBx联合TRUS-SBx可能适合作为临床显著前列腺癌的标准检测方法;PSA>20.0和<10.0 ng/ml时,MRI-TBx和TRUS-SBx均可能提供有效的肿瘤检测方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To explore whether prostate-specific antigen (PSA) affects the choice of prostate puncture methods by comparing MRI-ultrasound fusion targeted biopsy (MRI-TBx) with transrectal ultrasound systematic biopsy (TRUS-SBx) in the detection of prostate cancer (PCa), clinically significant prostate cancer (csPCa) and non-clinically significant prostate cancer (nsPCa) in different PSA groups (<10.0,10.0-20.0 and>20.0 ng ml-1).
METHODS: A total of 190 patients with 215 lesions who underwent both MRI-TBx and TRUS-SBx were included in this retrospective study. PSA was measured pre-operatively and stratified to three levels. The detection rates of PCa, csPCa and nsPCa through different methods (MRI-TBx, TRUS-SBx, or MRI-TBx +TRUS SBx) were compared with stratification by PSA.
RESULTS: Among the 190 patients, the histopathological results revealed PCa in 126 cases, including 119 csPCa. In PSA <10.0 ng ml-1 group, although the detection rates of PCa and csPCa by MRI-TBx were higher than those of TRUS-SBx, no significant differences were observed (p = 0.741; p = 0.400). In PSA 10.0-20.0 ng ml-1 group, difference between the detection rate of csPCa with TRUS-SBx and the combined method was statistically significant (p = 0.044). As for PSA >20.0 ng ml-1, MRI-TBx had a higher csPCa rate than TRUS-SBx with no statistical significance noted (p = 0.600).
CONCLUSION: MRI-TBx combined with TRUS-SBx could be suitable as a standard detection approach for csPCa in patients with PSA 10.0-20.0 ng ml-1. As for PSA >20.0 and <10.0 ng ml-1, both MRI-TBx and TRUS-SBx might provide effective solutions for tumor detection.
ADVANCES IN KNOWLEDGE: This study gives an account of choosing appropriate prostate puncture methods through PSA level.
引用
- Liu Y, Dong L, Xiang L, et al. Does PSA level affect the choice of prostate puncture methods among MRI-ultrasound fusion targeted biopsy, transrectal ultrasound systematic biopsy or the combination of both? Br J Radiol. 2021. PMID: 34133228. doi:10.1259/bjr.20210312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。